Current Neuro-Oncology

Volume 27 Number 5
20 February 2025

Home > Publications > Current Neuro-Oncology > Volume 27, Year 2025 > Number 5, 20 February

Feng L, Wang S, Han Y, Liu X, Mu X, Wang Y, Li J, Zhang F, Tian J, Liu Q, Han X, Zhu S, Wang Z, Zhang W, Gong L.
Chordoid glioma with uncommon papillary and fusiform structures.
Pathol Res Pract. 2025 Feb 11;267:155841. doi: 10.1016/j.prp.2025.155841. PMID: 39970814. Observational study˰ ˍ

Jiang K, Kalluri A, Odonkor M, Heinemann DM, Weber-Levine C, Raj D, Materi J, Rakovec M, Pineda E, Redmond KJ, Romo C, Kamson DO, Holdhoff M, Schreck KC, González Sánchez JJ, Bettegowda C, Rincon-Torroella J.
Trends in the Management of Oligodendrogliomas: A Multinational and Multidisciplinary Survey Study.
World Neurosurg. 2025 Feb 11:123716? doi: 10.1016/j.wneu.2025.123716? PMID: 39947316. Observational study˰ ˍ

Orasanu CI, Aschie M, Deacu M, Bosoteanu M, Vamesu S, Enciu M, Cozaru GC, Mitroi AF, Ghitoi SA, Cretu AM, Ursica OA, Voda RI.
Comparative Clinical-Imaging and Histogenetic Analysis Between Astrocytoma IDH-Mutant Grade 4 and Glioblastoma IDH-Wildtype-Is There Really a Worse One?
Diagnostics (Basel). 2025 Feb 11;15(4):438. doi: 10.3390/diagnostics15040438. PMID: 40002588. Observational study. ˍ

Osawa S, Kawauchi D, Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Fujita S, Tsuchiya T, Matsumi J, Sato T, Narita Y.
Outcomes of awake surgery for recurrent glioblastoma: A single-institution retrospective analysis.
J Clin Neurosci. 2025 Feb 13;134:111113. doi: 10.1016/j.jocn.2025.111113? PMID: 39951833. Observational study. ˍ

Stone TJ, Pickles JC, Ogunbiyi O, Yasin SA, Taylor CA, Ahmed SW, Chalker J, Dryden C, Slodkowska I, Pang E, Kristiansen M, Williams R, Tutill H, Williams CA, Madhan GK, Forrest L, Brooks T, Hubank M, Hughes D, Proszek P, Pietka G, Peat E, Hargrave D, Jacques TS.
The tumour microenvironment of pilocytic astrocytoma evolves over time via enrichment for microglia.
Acta Neuropathol Commun. 2025 Feb 13;13(1):30. doi: 10.1186/s40478-024-01922-9. PMID: 39948623. Observational study. ˍ

Aduwo JY, McClelland S 3rd.
Censoring Analysis of the INvestigating VorasiDenib In GliOma (INDIGO) Phase III Randomized Controlled Trial.
Am J Clin Oncol. 2025 Feb 14. doi: 10.1097/COC.0000000000001175. PMID: 39950862. Editorial. ˍ
RELATED ARTICLE
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF.
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
N Engl J Med. 2023 Jun 4. doi: 10.1056/NEJMoa2304194. PMID: 37272516. Interventional study. ˍ

Kiesel B, Borkovec M, Furtner J, Roetzer-Pejrimovsky T, Nenning KH, Greutter L, Miller-Michlits Y, Widhalm G, Woehrer A.
Sex-specific differences in DNA methylation defining prognostically relevant subgroups in glioblastoma.
J Neurosurg. 2025 Feb 14:1-10. doi: 10.3171/2024.9.JNS24665. PMID: 39951709. Laboratory investigation; Observational study˰ ˍ

Snider S, Gagliardi F, De Domenico P, Comai S, Bertazzo A, Nasini S, Barzon B, Ruban A, Roncelli F, Mortini P.
Preoperative Peripheral Blood Serotonin and Kynurenine Levels Are Associated With Oncological Outcomes in Glioblastoma IDH-wt Patients.
Int J Tryptophan Res. 2025 Feb 14;18:11786469241312475. doi: 10.1177/11786469241312475. PMID: 39959303. Observational study. ˍ

Mair MJ, Leibetseder A, Heller G, Tomasich E, Müller L, Busse I, Wöhrer A, Kiesel B, Widhalm G, Eckert F, Weis S, Pichler J, Preusser M, Berghoff AS.
Clinical characteristics, molecular reclassification trajectories and DNA methylation patterns of long- and short-term survivors of WHO grade II and III glioma.
J Neurol. 2025 Feb 15;272(3):210. doi: 10.1007/s00415-025-12923-6. PMID: 39954095. Observational study. ˍ

Awad F, Abdallah F, Alhalabieh A, Aljaafreh I, Naserallah S, Lahham EE.
A rare case of sporadic metastatic colorectal cancer with glioblastoma multiforme: a challenging clinical scenario.
J Surg Case Rep. 2025 Feb 17;2025(2):rjae708. doi: 10.1093/jscr/rjae708. PMID: 39963396. Case report. ˍ

Innes SC, Yin L, Finnerty GT.
Stroke in adults with primary intracranial tumours.
J Neurol. 2025 Feb 17;272(3):212. doi: 10.1007/s00415-025-12929-0. PMID: 39960529. Observational study. ˍ

Jeong SM, Heo J, Choi K, Taegyun P, Oh SY, Yu J, Kang D.
Association between maternal cancer and the incidence of cancer in offspring.
Eur J Epidemiol. 2025 Feb 17. doi: 10.1007/s10654-025-01206-z. PMID: 39960651. Observational study. ˍ

Lin P, Pang JS, Lin YD, Qin Q, Lv JY, Zhou GQ, Tan TM, Mo WJ, Chen G.
Tumour surface regularity predicts survival and benefit from gross total resection in IDH-wildtype glioblastoma patients.
Insights Imaging. 2025 Feb 17;16(1):42. doi: 10.1186/s13244-025-01900-2. PMID: 39961919. Observational study. ˍ

Watanabe T, Noto S, Natsumeda M, Kimura S, Ikarashi F, Tabata S, Takano M, Tsukamoto Y, Oishi M.
Improved health-related quality of life after rehabilitation in patients with brain tumors is not affected by tumor type.
Eur J Phys Rehabil Med. 2025 Feb 17. doi: 10.23736/S1973-9087.25.08573-9. PMID: 39960468. Observational study. ˍ

Huang M, Kang Z, Li S, Zhang B, Xiao Y, Li S, Li W.
Phase I clinical trial of a novel procaspase-3 activator SM-1 with temozolomide in recurrent high-grade gliomas.
Neoplasia. 2025 Feb 18;61:101141. doi: 10.1016/j.neo.2025.101141. PMID: 39970841. Interventional study. ˍ

Park YW, Jang G, Kim SB, Han K, Shin NY, Ahn SS, Chang JH, Kim SH, Jain R, Lee SK.
Leptomeningeal metastases at recurrence in IDH-wildtype glioblastomas: incidence, risk factors, and prognosis based on postcontrast FLAIR imaging.
Eur Radiol. 2025 Feb 18. doi: 10.1007/s00330-025-11447-x. PMID: 39966177. Observational study˰ ˍ

Champeaux Depond C, Metellus P, Gross E, Appay R.
Vanishing Contrast Enhancement of a Diffuse Midline Glioma.
Neuropathology. 2025 Feb 19. doi: 10.1111/neup.70002. PMID: 39970957. Case report˰ ˍ

Rendo V, Lee EQ, Bossi C, Khuu N, Rudek MA, Pal S, Azazmeh N, Rashid R, Lin JR, Cusick M, Reynolds ARN, Fassinou ACR, Ayoub G, Malinowski S, Lapinskas E, Pisano W, Jeang J, Stopka SA, Regan MS, Spetz J, Desai A, Lieberman F, Palanichamy K, Fisher JD, Pelton K, Huang RY, Sarosiek KA, Nabors LB, Holdhoff M, Danda N, Strowd R, Desideri S, Walbert T, Ye X, Chakravarti A, Sorger PK, Santagata S, Agar NYR, Grossman SA, Alexander BM, Wen PY, Ligon KL, Beroukhim R.
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma.
Sci Transl Med. 2025 Feb 19;17(786):eadn6274. doi: 10.1126/scitranslmed.adn6274. PMID: 39970230. Interventional study˰ ˍ

Souweidane MM, Bander ED, Zanzonico P, Reiner AS, Manino N, Haque S, Carrasquillo JA, Lyashchenko SK, Thakur SB, Lewis JS, Donzelli M, Cheung NV, Larson SM, Kramer K, Pandit-Taskar N, Dunkel IJ.
Phase 1 dose-escalation trial using convection-enhanced delivery (CED) of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma (DIPG).
Neuro Oncol. 2025 Feb 19:noaf039. doi: 10.1093/neuonc/noaf039. PMID: 39969230. Interventional study˰ ˍ

Sun F, Zhu Y, Gan G, Xu Y, Xu X.
Therapeutic and prognostic impact of target volume delineation in postoperative radiotherapy for high-grade glioma patients with subventricular zone involvement.
Radiat Oncol. 2025 Feb 19;20(1):24. doi: 10.1186/s13014-025-02601-2. PMID: 39972483. Observational study. ˍ

Schneider M, Potthoff AL, Ahmadipour Y, Borger V, Clusmann H, Combs SE, Czabanka M, Dührsen L, Etminan N, Freiman TM, Gerlach R, Gessler F, Giordano FA, Gkika E, Goldbrunner R, Güresir E, Hamou H, Hau P, Ille S, Jägersberg M, Keric N, Khaleghi-Ghadiri M, König R, Konczalla J, Krenzlin H, Krieg S, McLean AL, Layer JP, Lehmberg J, Malinova V, Meyer B, Meyer HS, Miller D, Müller O, Musahl C, Pregler BEF, Rashidi A, Ringel F, Roder C, Rössler K, Rohde V, Sandalcioglu IE, Schäfer N, Schaub C, Schmidt NO, Schubert GA, Seidel C, Seliger C, Senft C, Shawarba J, Steinbach J, Stöcklein V, Stummer W, Sure U, Tabatabai G, Tatagiba M, Thon N, Timmer M, Wach J, Wagner A, Wirtz CR, Zeiler K, Zeyen T, Schuss P, Surges R, Fuhrmann C, Paech D, Schmid M, Borck Y, Pietsch T, Struck R, Radbruch A, Helmstaedter C, Németh R, Herrlinger U, Vatter H.
The ATLAS/NOA-29 study protocol: a phase III randomized controlled trial of anterior temporal lobectomy versus gross-total resection in newly-diagnosed temporal lobe glioblastoma.
BMC Cancer. 2025 Feb 20;25(1):306. doi: 10.1186/s12885-025-13682-3. PMID: 39979825. Interventional study protocol. ˍ

van der Weide HL, Buunk AM, Siebenga FF, Langendijk JA, Bannink-Gawryszuk A, Bosma I, Enting RH, van der Hoorn A, Jeltema HR, Wagemakers M, Groen RJM, Walenkamp-Hageman AME, Nuver J, Kramer MCA, Spikman JM.
Neurocognitive function in lower grade glioma patients selected for proton radiotherapy: real-world data from a prospective cohort study.
J Neurooncol. 2025 Feb 20. doi: 10.1007/s11060-025-04973-7. PMID: 39976896. Observational study. ˍ

Zhao X, Li C, Wang K, Zhang Y, Wan H, Yang P, Zhou D.
MR-guided laser interstitial thermal therapy followed by early application of temozolomide for recurrent IDH-wildtype glioblastomas: preliminary results from a prospective study.
Neurosurg Rev. 2025 Feb 20;48(1):254. doi: 10.1007/s10143-025-03402-7. PMID: 39971799. Observational study˰ ˍ